AI Terminal
Novo Nordisk
Director's Dealing • Nov 13, 2024
3375_rpt_2024-11-13_58448252-e514-4845-9146-b1fbcb2d1caa.pdf
Director's Dealing
Open in ViewerOpens in native device viewer
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 13 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated |
||||||
|---|---|---|---|---|---|---|
| a) | Name of the Board member/Executive/Associated Person |
Choi Lai Christina Law | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) |
Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90
| a) | Description of the financial instrument, type of instrument, |
ADRs | |||
|---|---|---|---|---|---|
| Identification code | NVO | ||||
| b) | Nature of the transaction | Purchase of ADRs | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 743.31 | 1,300 ADRs | ||||
| d) | Aggregated information | ||||
| • Aggregated volume |
1,300 ADRs | ||||
| • Price |
DKK 966,301.02 | ||||
| e) | Date of the transaction | 2024-11-12 | |||
| f) | Place of the transaction | New York Stock Exchange |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: Ambre James-Brown +45 3079 9289 [email protected]
Investors: Jacob Martin Wiborg Rode +45 3075 5956 [email protected]
Sina Meyer +45 3079 6656 [email protected] Liz Skrbkova (US) +1 609 917 0632 [email protected]
David Heiberg Landsted +45 3077 6915 [email protected]
Ida Schaap Melvold +45 3077 5649 [email protected]
Novo Nordisk A/S Investor Relations
Novo Alle 1 2880 Bagsværd Denmark
Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90
Frederik Taylor Pitter (US)
+1 609 613 0568 [email protected]
Novo Nordisk A/S Investor Relations
Novo Alle 1 2880 Bagsværd Denmark
Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90
Company announcement No 88 / 2024